表柔比星与5-氟尿嘧啶联合静脉注射治疗晚期肝癌的II期研究

Mikael J. Kajanti, Seppo O. Pyrhönen
{"title":"表柔比星与5-氟尿嘧啶联合静脉注射治疗晚期肝癌的II期研究","authors":"Mikael J. Kajanti,&nbsp;Seppo O. Pyrhönen","doi":"10.1016/0277-5379(91)90428-G","DOIUrl":null,"url":null,"abstract":"<div><p>Between August 1986 and September 1990, 22 previously untreated non-cirrhotic patients with measurable unresectable primary liver cancer were treated every 4 weeks with a combination of epirubicin and 5-fluorouracil. The dose of epirubicin was escalated; the starting dose was 40 mg/m<sup>2</sup>, the second dose was 50 mg/m<sup>2</sup> and thereafter 60 mg/m<sup>2</sup> during subsequent cycles. The dose of 5-fluorouracil was always 800 mg/m<sup>2</sup>. Objective response rate was 14%. Most of the patients experienced only mild haematological toxicity, and no other dose limiting toxicity was observed. Nonetheless, increasing the dose would probably not have increased the response rate.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90428-G","citationCount":"8","resultStr":"{\"title\":\"Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma\",\"authors\":\"Mikael J. Kajanti,&nbsp;Seppo O. Pyrhönen\",\"doi\":\"10.1016/0277-5379(91)90428-G\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Between August 1986 and September 1990, 22 previously untreated non-cirrhotic patients with measurable unresectable primary liver cancer were treated every 4 weeks with a combination of epirubicin and 5-fluorouracil. The dose of epirubicin was escalated; the starting dose was 40 mg/m<sup>2</sup>, the second dose was 50 mg/m<sup>2</sup> and thereafter 60 mg/m<sup>2</sup> during subsequent cycles. The dose of 5-fluorouracil was always 800 mg/m<sup>2</sup>. Objective response rate was 14%. Most of the patients experienced only mild haematological toxicity, and no other dose limiting toxicity was observed. Nonetheless, increasing the dose would probably not have increased the response rate.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90428-G\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/027753799190428G\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190428G","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

摘要

在1986年8月至1990年9月期间,22名未接受治疗的非肝硬化不可切除原发性肝癌患者每4周接受一次表柔比星和5-氟尿嘧啶联合治疗。表柔比星的剂量逐渐增加;开始剂量为40 mg/m2,第二次剂量为50 mg/m2,随后的周期为60 mg/m2。5-氟尿嘧啶剂量始终为800 mg/m2。客观有效率为14%。大多数患者仅出现轻度血液学毒性,未观察到其他剂量限制性毒性。尽管如此,增加剂量可能不会增加反应率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma

Between August 1986 and September 1990, 22 previously untreated non-cirrhotic patients with measurable unresectable primary liver cancer were treated every 4 weeks with a combination of epirubicin and 5-fluorouracil. The dose of epirubicin was escalated; the starting dose was 40 mg/m2, the second dose was 50 mg/m2 and thereafter 60 mg/m2 during subsequent cycles. The dose of 5-fluorouracil was always 800 mg/m2. Objective response rate was 14%. Most of the patients experienced only mild haematological toxicity, and no other dose limiting toxicity was observed. Nonetheless, increasing the dose would probably not have increased the response rate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信